forumAdmin
04-01-2008, 07:22 PM
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE? (lisdexamfetamine dimesylate).
External site More Info here... (http://www.medicalnewstoday.com/articles/93049.php)
Please return here to comment...............
External site More Info here... (http://www.medicalnewstoday.com/articles/93049.php)
Please return here to comment...............